ADL Amdl,

TUSTIN, Calif., Sept. 4 /PRNewswire/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. Set forth in this news release are highlights of the recent Rudd Report including AMDL's achievements as cited by Mr. Rudd. Mr. Rudd, a nationally syndicated columnist, is CEO of Savannah Capital Management, a money management firm. 1. We feel that it is important to recognize that on an operating cash basis, AMDL came close to breaking even in the first six months of this year and will likely be even or operating cash positive by the end of the year. 2. With AMDL's most recent round of funding now completed, we look for the additional funds to enable Jade to generate net revenues for the year 2007 to $14.2 million or about double what Jade did in 2006. 3. As Jade's new distribution agreements develop their full potential, we believe that net sales will again double by the end of 2008, reaching a total of $28.4 million. That should result in gross profits for the company of about $7.1 million in 2007 and about $14.2 million in 2008. 4. We believe that Jade will be able to show a net profit at the close of 2008 of approximately $4.26 million, or 15 percent of net sales. With 12.58 million shares outstanding after the recent financing that equates to a profit of about 35 cents per share. 5. AMDL will receive FDA approval for DR-70(R) sometime during the fourth quarter of 2007. As such DR-70(R) will not contribute significantly to 2007 revenues or profits. 6. An approval by the FDA of DR-70(R) in 2007 will result in about $16 million in gross profits for AMDL in 2008, of which at least $12 million will fall to the bottom line pre-tax because the majority of all overhead expenses are already covered in the Jade numbers. The after-tax net should then be about $8 million, or about 66 cents per share. 7. We do not believe that DR-70(R) will have an appreciable effect on AMDL's earnings in this calendar year even if it is approved in 2007. While we believe that receiving approval is certainly an important factor to the company's ongoing success, we also continue to stand by our opinion that the importance of FDA approval has diminished somewhat in light of the company's current and projected performance in China. 8. We feel that DR-70(R) is likely to be approved in China before the FDA acts on AMDL's application. As such, we are basing our projection for AMDL's performance in 2007 exclusively on the performance of Jade. 9. With DR-70(R) approval, the two divisions of AMDL would show total earnings for 2008 of $12.26 million, or about $1.01 per share. We are assuming a multiple of 22 times earnings, which is comparable other companies in the same industry. Therefore, we continue to stand by our 2008 target for AMDL's shares to $22 per share. 10. From a risk viewpoint, we feel relatively certain that the Jade division will produce earnings of 35 cents per share in 2008. A multiple of 22 equates to $7.70 per share. Therefore, we feel that the downside risk is not only minimal but that there is an opportunity for substantial appreciation in the share price even without FDA approval of DR-70(R). About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/. About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. About The Rudd Report Disclaimer: This disclaimer is an integral part of our service. Please read it before investing in any security on which we report. Opinions are solely those of the staff of The Rudd Report and are subject to change without notice. Our reports are for information only and we do not offer securities or solicit the offer of securities of any company. Our reports are to inform the public and not to promote any company or its securities. We do not inform any company in advance of the nature or conclusions of our reports nor can a company change what we write. In the case of AMDL we received a fee for coverage of the current quarter in the amount of $6,000. Our reports contain factual statements and opinions. We derive these factual statements from sources that we believe are accurate. However, we do not represent that the facts presented are accurate or complete. Furthermore, the information contained in this report may become inaccurate because of the passage of time and should therefore be read for historical information only. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, Investor Relations of AMDL, Inc, +1-949-707-5365, voice mail, +1-714-505-4460 Web site: http://www.amdl.com/

Copyright